Camille C. Gunderson, MD, assistant professor of gynecologic oncology, Stephenson Cancer Center, discusses the use of PARP inhibitors in all-comers with ovarian cancer.
Camille C. Gunderson, MD
Advertisement
Articles by Camille C. Gunderson, MD
Camille C. Gunderson, MD, discusses the phase III open-label GOG-252 trial in advanced ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Gunderson on the GOG-252 Trial in Advanced Ovarian CancerPublished: September 19th 2019 | Updated:
Dr. Gunderson on the Use of PARP Inhibitors in All-Comers With Ovarian CancerPublished: April 9th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5